![Frontiers | Rivaroxaban plus aspirin vs. dual antiplatelet therapy in endovascular treatment in peripheral artery disease and analysis of medication utilization of different lesioned vascular regions Frontiers | Rivaroxaban plus aspirin vs. dual antiplatelet therapy in endovascular treatment in peripheral artery disease and analysis of medication utilization of different lesioned vascular regions](https://www.frontiersin.org/files/Articles/1285553/fsurg-10-1285553-HTML/image_m/fsurg-10-1285553-g001.jpg)
Frontiers | Rivaroxaban plus aspirin vs. dual antiplatelet therapy in endovascular treatment in peripheral artery disease and analysis of medication utilization of different lesioned vascular regions
![PDF) Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials PDF) Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials](https://i1.rgstatic.net/publication/354267694_Low-dose_rivaroxaban_and_aspirin_among_patients_with_peripheral_artery_disease_a_meta-analysis_of_the_COMPASS_and_VOYAGER_trials/links/613816855c10801fe182301a/largepreview.png)
PDF) Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials
![Antithrombotic Therapy in Peripheral Artery Disease: Generating and Translating Evidence Into Practice - ScienceDirect Antithrombotic Therapy in Peripheral Artery Disease: Generating and Translating Evidence Into Practice - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0735109717416378-fx1.jpg)
Antithrombotic Therapy in Peripheral Artery Disease: Generating and Translating Evidence Into Practice - ScienceDirect
![Rivaroxaban plus aspirin increases major bleeding in patients with chronic CAD, PAD | Latest news for Doctors, Nurses and Pharmacists | Pharmacy Rivaroxaban plus aspirin increases major bleeding in patients with chronic CAD, PAD | Latest news for Doctors, Nurses and Pharmacists | Pharmacy](https://pubmiddleware.mims.com/resource/image/EB62169B-33BD-4810-90A6-A68300B908C0/OriginalThumbnail/THUMBNAIL_Fotolia_86009033_Subscription_Monthly_M.jpg)
Rivaroxaban plus aspirin increases major bleeding in patients with chronic CAD, PAD | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
![JCDD | Free Full-Text | Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions JCDD | Free Full-Text | Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions](https://www.mdpi.com/jcdd/jcdd-10-00164/article_deploy/html/images/jcdd-10-00164-g001.png)
JCDD | Free Full-Text | Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions
![Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial - The Lancet Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/51af3210-8169-49d1-8be2-17db2876e0ce/gr3.jpg)
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial - The Lancet
![Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients | Arteriosclerosis, Thrombosis, and Vascular Biology Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients | Arteriosclerosis, Thrombosis, and Vascular Biology](https://www.ahajournals.org/cms/asset/51ebae56-7673-450f-a625-a5945ab02032/10ga01.jpg)
Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients | Arteriosclerosis, Thrombosis, and Vascular Biology
![Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy | Future Cardiology Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy | Future Cardiology](https://www.futuremedicine.com/cms/10.2217/fca-2019-0091/asset/images/medium/figure1.gif)
Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy | Future Cardiology
![Peripheral Matters | Peripheral Artery Disease: Moving From Awareness to Action - American College of Cardiology Peripheral Matters | Peripheral Artery Disease: Moving From Awareness to Action - American College of Cardiology](https://www.acc.org//-/media/Non-Clinical/Images/2023/09/CARDIOLOGY/30/PAD-1600x1667.jpg)
Peripheral Matters | Peripheral Artery Disease: Moving From Awareness to Action - American College of Cardiology
![Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease – touchCARDIO Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease – touchCARDIO](https://www.touchcardio.com/wp-content/uploads/sites/4/2021/07/Morrison-Figure-1.png)